153 related articles for article (PubMed ID: 30940460)
1. Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient.
Pande A; Dubberke ER
Infect Dis Clin North Am; 2019 Jun; 33(2):485-500. PubMed ID: 30940460
[TBL] [Abstract][Full Text] [Related]
2. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic approach and therapy for cytomegalovirus (CMV) infection following allogeneic stem cell transplantation].
Beader N; Kalenić S; Labar B
Lijec Vjesn; 2011; 133(11-12):389-96. PubMed ID: 22329295
[TBL] [Abstract][Full Text] [Related]
4. [Ganciclovir treatment failure in adult allogeneic hematopoietic stem cell transplant recipients with cytomegalovirus infection--a single centre experience].
Vejražková E; Hubáček P; Kutová R; Plíšková L; Košťál M; Štěpánová V; Zavřelová A; Radocha J; Malá E; Žák P
Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):160-8. PubMed ID: 26448304
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
[TBL] [Abstract][Full Text] [Related]
6. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
[TBL] [Abstract][Full Text] [Related]
7. Delayed-onset primary cytomegalovirus disease after liver transplantation.
Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
[TBL] [Abstract][Full Text] [Related]
8. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
9. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
10. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB
Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023
[TBL] [Abstract][Full Text] [Related]
11. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients.
Limaye AP
Semin Respir Infect; 2002 Dec; 17(4):265-73. PubMed ID: 12497543
[TBL] [Abstract][Full Text] [Related]
12. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.
Li F; Kenyon KW; Kirby KA; Fishbein DP; Boeckh M; Limaye AP
Clin Infect Dis; 2007 Aug; 45(4):439-47. PubMed ID: 17638191
[TBL] [Abstract][Full Text] [Related]
13. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Hebart H; Kanz L; Jahn G; Einsele H
Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant.
Marchesi F; Pimpinelli F; Ensoli F; Mengarelli A
Hematol Oncol; 2018 Apr; 36(2):381-391. PubMed ID: 28660653
[TBL] [Abstract][Full Text] [Related]
15. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
16. Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient.
Chen F; Bando T; Hanaoka N; Fukuse T; Hasegawa S; Wada H
Jpn J Thorac Cardiovasc Surg; 2005 Oct; 53(10):562-4. PubMed ID: 16279588
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
Tsinontides AC; Bechtel TP
Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
[TBL] [Abstract][Full Text] [Related]
18. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
19. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Reddy AJ; Zaas AK; Hanson KE; Palmer SM
J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
[TBL] [Abstract][Full Text] [Related]
20. Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
Deback C; Burrel S; Varnous S; Carcelain G; Conan F; Aït-Arkoub Z; Autran B; Gandjbakhch I; Agut H; Boutolleau D
Antivir Ther; 2015; 20(2):249-54. PubMed ID: 25219330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
